Greenhaven Road Capital reported a +14% return in the second quarter of 2025, with YTD returns under +1%. The Russell 2000 has returned -1.8% YTD. Lifecore Biomedical, Inc. (NASDAQ:LFCR) gained 30.05% over the last 52 weeks, closing at $7.40 per share on August 18, 2025, with a market cap of $276.818 million.

Greenhaven Road Capital highlighted Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its second-quarter 2025 investor letter. Lifecore is an integrated contract development and manufacturing organization. The company’s stock had a one-month return of -0.54% and has shown strong growth over the past year.

Greenhaven Road Capital believes Lifecore Biomedical, Inc. (NASDAQ:LFCR) has high expected value. The company operates at 20% capacity with 15% EBITDA margins. While not among the 30 most popular stocks among hedge funds, Lifecore is held by 12 hedge fund portfolios. The company offers potential as an investment, but AI stocks may have greater upside potential.

Read more at Yahoo Finance: Does LifeCore (LFCR) Have a High Expected Value?